Sarepta Long Term Debt vs Long Term Debt Total Analysis

SRPT Stock

USD 107.95 1.51 1.38%

Sarepta Therapeutics financial indicator trend analysis is much more than just breaking down Sarepta Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sarepta Therapeutics is a good investment. Please check the relationship between Sarepta Therapeutics Long Term Debt and its Long Term Debt Total accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Long Term Debt vs Long Term Debt Total

Long Term Debt vs Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sarepta Therapeutics Long Term Debt account and Long Term Debt Total. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Sarepta Therapeutics' Long Term Debt and Long Term Debt Total is 0.98. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Long Term Debt Total in the same time period over historical financial statements of Sarepta Therapeutics, assuming nothing else is changed. The correlation between historical values of Sarepta Therapeutics' Long Term Debt and Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Sarepta Therapeutics are associated (or correlated) with its Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt Total has no effect on the direction of Long Term Debt i.e., Sarepta Therapeutics' Long Term Debt and Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

0.98

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Long Term Debt

Long-term debt is a debt that Sarepta Therapeutics has held for over one year. Long-term debt appears on Sarepta Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Sarepta Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Long Term Debt Total

Most indicators from Sarepta Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sarepta Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.At this time, Sarepta Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 35.1 M in 2025, whereas Enterprise Value Multiple is likely to drop (27.16) in 2025.

	2024	2025 (projected)
Non Recurring	199.2M	209.2M
Interest Income	77.8M	81.7M

Non Recurring Interest Income

Sarepta Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Non Current Liabilities Total	Other Current Assets	Other Assets	Property Plant Equipment	Net Receivables
Total Assets		0.74	0.96	0.82	0.97	0.5	-0.97	0.92	0.6	0.98	0.85	0.98	-0.3	0.95	0.81	0.98	0.98	0.94	1.0	0.83	-0.3	0.98	0.77	0.48	0.98	0.89
Other Current Liab	0.74		0.85	0.44	0.78	0.84	-0.8	0.81	0.08	0.8	0.88	0.64	-0.21	0.75	0.85	0.8	0.78	0.83	0.72	0.71	-0.21	0.75	0.86	0.09	0.81	0.86
Total Current Liabilities	0.96	0.85		0.7	0.98	0.66	-0.97	0.97	0.43	0.99	0.93	0.9	-0.26	0.92	0.86	0.98	0.98	0.99	0.95	0.85	-0.26	0.96	0.85	0.34	0.99	0.96
Total Stockholder Equity	0.82	0.44	0.7		0.75	0.29	-0.75	0.7	0.52	0.76	0.6	0.83	-0.38	0.86	0.68	0.83	0.7	0.7	0.83	0.79	-0.38	0.7	0.61	0.3	0.75	0.65
Property Plant And Equipment Net	0.97	0.78	0.98	0.75		0.62	-0.95	0.99	0.44	0.99	0.87	0.9	-0.26	0.93	0.84	0.98	0.96	0.98	0.95	0.89	-0.26	0.95	0.81	0.32	0.98	0.95
Net Debt	0.5	0.84	0.66	0.29	0.62		-0.56	0.71	-0.37	0.6	0.8	0.35	-0.04	0.53	0.88	0.61	0.53	0.69	0.47	0.7	-0.04	0.48	0.9	-0.34	0.61	0.79
Retained Earnings	-0.97	-0.8	-0.97	-0.75	-0.95	-0.56		-0.92	-0.54	-0.97	-0.87	-0.93	0.34	-0.95	-0.81	-0.97	-0.97	-0.95	-0.96	-0.8	0.34	-0.96	-0.78	-0.44	-0.98	-0.9
Accounts Payable	0.92	0.81	0.97	0.7	0.99	0.71	-0.92		0.31	0.97	0.88	0.82	-0.25	0.89	0.87	0.96	0.92	0.98	0.9	0.92	-0.25	0.9	0.84	0.19	0.95	0.97
Cash	0.6	0.08	0.43	0.52	0.44	-0.37	-0.54	0.31		0.5	0.19	0.72	-0.24	0.5	0.04	0.46	0.58	0.37	0.63	0.17	-0.24	0.63	-0.01	0.89	0.5	0.22
Non Current Assets Total	0.98	0.8	0.99	0.76	0.99	0.6	-0.97	0.97	0.5		0.89	0.92	-0.25	0.93	0.83	0.98	0.98	0.98	0.97	0.86	-0.25	0.97	0.81	0.38	0.99	0.94
Non Currrent Assets Other	0.85	0.88	0.93	0.6	0.87	0.8	-0.87	0.88	0.19	0.89		0.77	-0.19	0.82	0.91	0.9	0.87	0.94	0.84	0.82	-0.19	0.84	0.95	0.11	0.9	0.95
Cash And Short Term Investments	0.98	0.64	0.9	0.83	0.9	0.35	-0.93	0.82	0.72	0.92	0.77		-0.32	0.93	0.72	0.93	0.95	0.86	0.99	0.72	-0.32	0.96	0.67	0.61	0.93	0.78
Common Stock Total Equity	-0.3	-0.21	-0.26	-0.38	-0.26	-0.04	0.34	-0.25	-0.24	-0.25	-0.19	-0.32		-0.49	-0.23	-0.34	-0.25	-0.23	-0.3	-0.31	1.0	-0.24	-0.19	-0.16	-0.28	-0.19
Common Stock Shares Outstanding	0.95	0.75	0.92	0.86	0.93	0.53	-0.95	0.89	0.5	0.93	0.82	0.93	-0.49		0.83	0.97	0.91	0.9	0.95	0.85	-0.49	0.9	0.77	0.38	0.95	0.85
Short Term Investments	0.81	0.85	0.86	0.68	0.84	0.88	-0.81	0.87	0.04	0.83	0.91	0.72	-0.23	0.83		0.87	0.79	0.87	0.8	0.86	-0.23	0.76	0.98	-0.01	0.85	0.9
Other Stockholder Equity	0.98	0.8	0.98	0.83	0.98	0.61	-0.97	0.96	0.46	0.98	0.9	0.93	-0.34	0.97	0.87		0.95	0.97	0.97	0.9	-0.34	0.94	0.84	0.32	0.98	0.94
Total Liab	0.98	0.78	0.98	0.7	0.96	0.53	-0.97	0.92	0.58	0.98	0.87	0.95	-0.25	0.91	0.79	0.95		0.95	0.98	0.78	-0.25	1.0	0.76	0.5	0.98	0.9
Property Plant And Equipment Gross	0.94	0.83	0.99	0.7	0.98	0.69	-0.95	0.98	0.37	0.98	0.94	0.86	-0.23	0.9	0.87	0.97	0.95		0.93	0.9	-0.23	0.93	0.87	0.24	0.97	0.98
Total Current Assets	1.0	0.72	0.95	0.83	0.95	0.47	-0.96	0.9	0.63	0.97	0.84	0.99	-0.3	0.95	0.8	0.97	0.98	0.93		0.81	-0.3	0.98	0.75	0.5	0.97	0.87
Intangible Assets	0.83	0.71	0.85	0.79	0.89	0.7	-0.8	0.92	0.17	0.86	0.82	0.72	-0.31	0.85	0.86	0.9	0.78	0.9	0.81		-0.31	0.74	0.85	-0.07	0.83	0.93
Common Stock	-0.3	-0.21	-0.26	-0.38	-0.26	-0.04	0.34	-0.25	-0.24	-0.25	-0.19	-0.32	1.0	-0.49	-0.23	-0.34	-0.25	-0.23	-0.3	-0.31		-0.24	-0.19	-0.16	-0.28	-0.19
Non Current Liabilities Total	0.98	0.75	0.96	0.7	0.95	0.48	-0.96	0.9	0.63	0.97	0.84	0.96	-0.24	0.9	0.76	0.94	1.0	0.93	0.98	0.74	-0.24		0.73	0.55	0.97	0.87
Other Current Assets	0.77	0.86	0.85	0.61	0.81	0.9	-0.78	0.84	-0.01	0.81	0.95	0.67	-0.19	0.77	0.98	0.84	0.76	0.87	0.75	0.85	-0.19	0.73		-0.09	0.81	0.92
Other Assets	0.48	0.09	0.34	0.3	0.32	-0.34	-0.44	0.19	0.89	0.38	0.11	0.61	-0.16	0.38	-0.01	0.32	0.5	0.24	0.5	-0.07	-0.16	0.55	-0.09		0.42	0.08
Property Plant Equipment	0.98	0.81	0.99	0.75	0.98	0.61	-0.98	0.95	0.5	0.99	0.9	0.93	-0.28	0.95	0.85	0.98	0.98	0.97	0.97	0.83	-0.28	0.97	0.81	0.42		0.93
Net Receivables	0.89	0.86	0.96	0.65	0.95	0.79	-0.9	0.97	0.22	0.94	0.95	0.78	-0.19	0.85	0.9	0.94	0.9	0.98	0.87	0.93	-0.19	0.87	0.92	0.08	0.93

Click cells to compare fundamentals

Sarepta Therapeutics Account Relationship Matchups

Sarepta Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	3.0B	3.1B	3.1B	3.3B	3.8B	3.9B
Other Current Liab	22.1M	15.1M	406.5M	301.2M	346.4M	363.7M
Total Current Liabilities	416.0M	452.7M	619.6M	653.7M	751.7M	789.3M
Total Stockholder Equity	761.8M	928.0M	385.0M	859.3M	988.2M	1.0B
Property Plant And Equipment Net	282.2M	236.7M	245.0M	357.1M	410.7M	431.2M
Net Debt	(429.8M)	(977.5M)	650.6M	968.4M	1.1B	1.2B
Retained Earnings	(2.8B)	(3.2B)	(3.9B)	(4.4B)	(4.0B)	(3.8B)
Accounts Payable	111.1M	76.7M	95.9M	164.9M	189.7M	199.1M
Cash	1.5B	2.1B	966.8M	428.4M	492.7M	298.4M
Non Current Assets Total	499.5M	543.9M	570.5M	685.2M	788.0M	827.4M
Non Currrent Assets Other	13.0M	143.3M	286.6M	292.0M	335.8M	352.6M
Cash And Short Term Investments	1.9B	2.1B	2.0B	1.7B	1.9B	2.0B
Common Stock Shares Outstanding	78.0M	81.3M	87.6M	92.4M	106.3M	111.6M
Liabilities And Stockholders Equity	3.0B	3.1B	3.1B	3.3B	3.8B	3.9B
Other Stockholder Equity	3.6B	4.1B	4.3B	5.3B	6.1B	6.4B
Total Liab	2.2B	2.2B	2.7B	2.4B	2.8B	2.9B
Property Plant And Equipment Gross	282.2M	349.3M	393.9M	548.1M	630.3M	661.8M
Total Current Assets	2.5B	2.6B	2.6B	2.6B	3.0B	3.1B
Accumulated Other Comprehensive Income	3K	(20K)	(1.7M)	918K	1.1M	1.1M
Intangible Assets	13.6M	14.2M	7.6M	29.6M	34.1M	35.8M
Non Current Liabilities Total	1.8B	1.8B	2.1B	1.8B	2.0B	2.1B
Other Current Assets	4.1M	6.1M	108.1M	140.5M	161.6M	169.7M
Other Assets	295.5M	292.9M	286.6M	1.0	1.15	1.09
Property Plant Equipment	129.6M	190.4M	191.2M	245.0M	281.7M	295.8M
Net Receivables	138.6M	171.6M	259.7M	439.7M	505.7M	530.9M
Short Long Term Debt Total	1.2B	1.4B	1.6B	1.4B	1.6B	1.7B
Other Liab	10.2M	734.1M	628.8M	521.9M	600.2M	630.2M
Long Term Debt	992.5M	1.1B	1.5B	1.1B	1.3B	1.4B
Short Term Debt	193.6M	271.7M	15.5M	123.3M	141.8M	148.9M
Net Tangible Assets	805.7M	748.1M	913.8M	377.4M	434.0M	530.3M
Retained Earnings Total Equity	(1.6B)	(2.3B)	(2.8B)	(3.2B)	(2.9B)	(2.7B)
Long Term Debt Total	420.6M	681.9M	992.5M	1.1B	1.3B	1.3B
Capital Surpluse	2.6B	3.1B	3.6B	4.1B	4.8B	5.0B
Inventory	232.0M	186.2M	204.0M	322.9M	371.3M	389.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC